Why Amazon, Coinbase, and Eastman Chemical shares plummeted: analysis of the biggest losses on the stock market
There is a surge of anxiety on the US stock market. Friday’s trading ended with a noticeable decline: the indices seemed to release the accumulated tension, reacting to several factors at once. But the focus was not on abstract macro data, but on specific stocks of companies that found themselves under a barrage of sell-offs. Among them were Eastman Chemical, Coinbase, Amazon, Moderna, and Ingersoll Rand. Each of these companies’ declines were not accidental — there were stories behind the numbers.
Eastman Chemical: an industrial giant that failed to meet expectations
EMN:NYSE The company’s 21% drop in share price in a single day is not a correction, but a capitulation. Investors reacted not so much to the quarterly report itself as to its implications. Net profit was lower than expected, as was revenue. But most importantly, management sharply lowered its forecasts for the coming months.
Against the backdrop of declining demand in Europe and Asia, rising costs, and changes in the chemical sector, the company has been forced to lower its cash flow expectations. This has caused alarm among those who viewed the company’s shares as a stable industrial asset in their portfolios. Market capitalization plummeted by billions in a matter of hours.
Coinbase: when profits don’t save the day
COIN:NASDAQ seems to be doing well — earnings per share are up significantly and indicators are positive. But the numbers did not fool the market. Revenue was lower than expected. Transaction revenue declined, as did subscriptions. Forecasts are cautious. Against a backdrop of growing competition and an unstable cryptocurrency environment, this sounds like a warning.
Coinbase shares are losing up to 16% and, along with them, the trust of some investors. This is not the first time that the company’s business has looked attractive on paper but signaled deeper problems in its operating model.
Amazon: AWS is slowing down — and it’s serious
Amazon reported record revenue, strong profits, and steady growth in e-commerce and advertising. However, all of this was overshadowed by one division — cloud computing. AWS, always considered the driver of the future, suddenly faltered. Growth slowed and margins declined. For a highly valued company whose capitalization is based on forecasts, this is a risk.
Amazon’s shares fell by almost 8%. And although no one questions its long-term prospects, it is now clear that even the largest tech giants are vulnerable to shifts in key metrics.
Moderna: back to reality
The pandemic brought Moderna worldwide fame and rapid growth. But the market is not standing still. Vaccine sales are falling, and revenue is falling with them. The revenue forecast for the year has been lowered. Development of new drugs continues, but they are still far from monetization.
The company’s shares fell 8% in a single day. This is not a surprise — rather, it is a logical continuation of cooling interest. The days of super profits are over, and investors have yet to see what will replace them in the company’s future.
Ingersoll Rand: weak orders as a litmus test
Ingersoll Rand was considered a strong player in the industrial supply segment. Its quarterly report was solid. But one statement in the presentation triggered a chain reaction: the company noted a decline in new orders and caution among customers in their development plans. In the current situation, the market does not forgive doubts.
The company’s shares are losing more than 11%. This reflects general concerns about the real sector: capital spending is slowing, businesses are cautious, and logistics is once again becoming a risk factor. Nothing catastrophic — but the mood is spoiled.
What the market really showed
The collapse of a number of large stocks on August 1 was not just a reflection of specific corporate mistakes; it exposed the fragility of expectations. Investors in 2025 no longer react mechanically to figures: they look deeper, analyzing the quality of growth, revenue stability, cost structure, and customer behavior. The very fact that even profitable reports have triggered sell-offs indicates a sharp shift in investment focus.
The US stock market has entered a phase of reassessment. Tech giants, once seen as untouchable, are no longer immune to a downturn. Industrial and pharmaceutical companies now have to show not only profits, but also strategic clarity, accurate forecasts, and the ability to adapt to geopolitics and supply chains. This is an important signal for private and institutional investors. Strategies built on inertia no longer work. Selectivity, fundamental analysis, and the ability to respond quickly to shifting market priorities are required.
Who lost the most: key facts at a glance
| Company | Decline | Reason |
|---|---|---|
| Eastman Chemical | −21% | Forecast cut, declining demand |
| Coinbase | −16% | Missed revenue, weak transaction volume |
| Amazon | −8% | AWS slowdown, cautious guidance |
| Moderna | −8% | Drop in vaccine-related revenue |
| Ingersoll Rand | −11% | Fewer new orders, B2B market warning signal |
The massive decline in the shares of companies with different business models and in different sectors has shown that the market no longer believes in universal recipes. And this creates paradoxically favorable conditions for those who are ready not to follow trends, but to understand what is behind them.
If you are interested in which areas could become growth drivers in the coming months, take a look at the high-tech biotech sector. In our article “Genome editing and company shares: who will set the pace in the market in 2025?”, we analyze the prospects for companies working with CRISPR, base editing, and other breakthrough genome editing methods.
And if you are just starting out on your investment journey and want to build a strategy without panic and chaos, start with the basics. The article “How to learn to trade stocks: a step-by-step guide for future investors” will help you avoid key mistakes and choose your path in the stock market.
